Pregabalin is a Schedule V Controlled Substance in the United States
Pregabalin is classified as a Schedule V controlled substance by the U.S. Drug Enforcement Administration (DEA), representing the lowest potential for abuse among controlled substances. 1
Regulatory Classification
The DEA formally placed pregabalin into Schedule V of the Controlled Substances Act in 2005 2. This classification means that pregabalin has:
- An accepted medical use in the United States
- The lowest potential for abuse relative to Schedule I-IV substances
- Limited risk of physical or psychological dependence compared to higher schedules
Clinical Context
Multiple clinical guidelines consistently reference pregabalin's Schedule V status when discussing its use for neuropathic pain conditions 3. The FDA drug label explicitly states: "Pregabalin is a Schedule V controlled substance" 1.
Abuse Potential Considerations
While Schedule V represents low abuse potential, the evidence shows some concerning patterns:
- In recreational drug users, pregabalin (450 mg single dose) produced subjective ratings of "good drug effect," "high," and "liking" similar to diazepam 30 mg 1
- In controlled trials, 4% of pregabalin-treated patients reported euphoria as an adverse reaction, with rates ranging from 1-12% in certain populations 1
- Research has documented pregabalin abuse among patients with opioid dependency, with 12.1% of opiate-dependent patients testing positive for pregabalin without medical indication 4
Prescribing Implications
As a Schedule V substance, pregabalin requires:
- Standard prescription (not requiring the stricter controls of Schedule II-IV substances)
- Appropriate documentation and monitoring
- Heightened vigilance in patients with history of substance abuse disorders, particularly opioid dependency 1, 4, 5
The Schedule V classification balances pregabalin's legitimate therapeutic value for neuropathic pain, fibromyalgia, and seizures against its relatively low but documented potential for misuse.